B cells; T cells; alpha-synuclein; microglia; monocytes
Abstract :
[en] Parkinson's disease (PD) is characterised neuropathologically by the degeneration of dopaminergic neurons in the ventral midbrain, the accumulation of α-synuclein (α-syn) aggregates in neurons, and chronic neuroinflammation. In the past two decades, in vitro, ex vivo and in vivo studies have consistently shown the involvement of inflammatory responses mediated by microglia and astrocytes, which may be elicited by pathological α-syn or signals from affected neurons and other cell types, and are directly linked to neurodegeneration and disease development. Besides the prominent immune alterations seen in the central nervous system (CNS), including the infiltration of T-cells into the brain, more recent studies have demonstrated important changes in the peripheral immune profile within both the innate and adaptive compartments, particularly involving monocytes, CD4+ and CD8+ T-cells. This review aims to integrate the consolidated understanding of immune-related processes underlying the pathogenesis of PD, focusing on both central and peripheral immune cells, neuron-glia crosstalk as well as the central-peripheral immune interaction during the development of PD. Our analysis seeks to provide a comprehensive view of the emerging knowledge of the mechanisms of immunity in PD and the implications of this for better understanding the overall pathogenesis of this disease.
Research Center/Unit :
GIGA CRC In vivo Imaging-MoVeRe - ULiège
Disciplines :
Neurology
Author, co-author :
Roodveldt, Cintia; Centre for Molecular Biology and Regenerative Medicine-CABIMER, University of Seville-CSIC, Seville (41092), Spain ; Department of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, University of Seville, Seville (41009), Spain
Bernardino, Liliana; Health Sciences Research Center (CICS-UBI), Faculty of Health Sciences, University of Beira Interior, 6200-506, Covilhã, Portugal
Oztop-Cakmak, Ozgur; Department of Neurology, Faculty of Medicine, Koç University, Istanbul, Turkey
Dragic, Milorad; Laboratory for Neurobiology, Department of General Physiology and Biophysics, Faculty of Biology, University of Belgrade, 11000 Belgrade, Serbia ; Department of Molecular Biology and Endocrinology, "VINČA" Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia
Fladmark, Kari Espolin; Department of Biological Science, University of Bergen, 5006 Bergen, Norway
Ertan, Sibel; Department of Neurology, Faculty of Medicine, Koç University, Istanbul, Turkey
Busra, Aktas; Department of Molecular Biology and Genetics, Burdur Mehmet Akif Ersoy University, Burdur (15200), Turkey
Pita, Carlos; iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal
Ciglar, Lucia; AIT Austrian Institute of Technology GmbH, Center Health & Bioresources, Competence Unit Molecular Diagnostics, 1210 Vienna, Austria
Garraux, Gaëtan ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie du système nerveux
Williams-Gray, Caroline; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
Pacheco, Rodrigo; Laboratorio de Neuroinmunología, Centro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Huechuraba (8580702), Santiago, Chile ; Facultad de Medicina y Ciencia, Universidad San Sebastián, Providencia (7510156), Santiago, Chile
Romero-Ramos, Marina ; Department of Biomedicine & The Danish Research Institute of Translational Neuroscience - DANDRITE, Aarhus University, DK-8000 Aarhus C, Denmark
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30:1591-1601.
Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The incidence of Parkinson's disease: A systematic review and meta-analysis. Neuroepidemiology. 2016;46:292-300.
Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: Risk factors and prevention. Lancet Neurol. 2016;15:1257-1272.
Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and pathogenesis of Parkinson's syndrome. Annu Rev Pathol. 2023; 18:95-121.
Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013;136(Pt 8):2419-2431.
Titova N, Padmakumar C, Lewis SJG, Chaudhuri KR. Parkinson's: A syndrome rather than a disease? J Neural Transm (Vienna). 2017;124:907-914.
Jankovic J, Tan EK. Parkinson's disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91:795-808.
Cardinale A, Calabrese V. The intricate debate on neurodegeneration and neuroinflammation in Parkinson's disease: Which came first? Neural Regen Res. 2023;18:125-126.
Brundin P, Melki R. Prying into the prion hypothesis for Parkinson's disease. J Neurosci. 2017;37:9808-9818.
Cardinale A, Calabrese V, de Iure A, Picconi B. Alpha-Synuclein as a prominent actor in the inflammatory synaptopathy of Parkinson's disease. Int J Mol Sci. 2021;22:6517.
Li X, Sundquist J, Sundquist K. Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: A nationwide epidemiological study from Sweden. Neurodegener Dis. 2012;10(1-4):277-284.
Racette BA, Gross A, Vouri SM, Camacho-Soto A, Willis AW, Searles Nielsen S. Immunosuppressants and risk of Parkinson disease. Ann Clin Transl Neurol. 2018;5:870-875.
Li D, Mastaglia FL, Yau WY, Chen S, Wilton SD, Akkari PA. Targeted molecular therapeutics for Parkinson's disease: A role for antisense oligonucleotides? Mov Disord. 2022;37:2184-2190.
Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: A case-control study. Lancet Neurol. 2008;7:583-590.
Lee H, James WS, Cowley SA. LRRK2 in peripheral and central nervous system innate immunity: Its link to Parkinson's disease. Biochem Soc Trans. 2017;45:131-139.
Rideout HJ, Re DB. LRRK2 and the "LRRKtosome" at the crossroads of programmed cell death: Clues from RIP kinase relatives. Adv Neurobiol. 2017;14:193-208.
Matheoud D, Sugiura A, Bellemare-Pelletier A, et al. Parkinson's disease-related proteins PINK1 and Parkin repress mitochondrial antigen presentation. Cell. 2016;166:314-327.
Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. Lancet Neurol. 2020;19:170-178.
Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009;132(Pt 7):1783-1794.
Parlar SC, Grenn FP, Kim JJ, Baluwendraat C, Gan-Or Z. Classification of GBA1 variants in Parkinson's disease: The GBA1-PD browser. Mov Disord. 2023;38:489-495.
Al-Azzawi ZAM, Arfaie S, Gan-Or Z. GBA1 and the immune system: A potential role in Parkinson's disease? J Parkinsons Dis. 2022;12(s1):S53-S64.
Witoelar A, Jansen IE, Wang Y, et al. Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol. 2017;74:780-792.
Kang X, Ploner A, Wang Y, et al. Genetic overlap between Parkinson's disease and inflammatory bowel disease. Brain Commun. 2023;5:fcad002.
Hui KY, Fernandez-Hernandez H, Hu J, et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease. Sci Transl Med. 2018; 10:eaai7795.
Gardet A, Benita Y, Li C, et al. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol. 2010;185:5577-5585.
Liao PH, Chiang HL, Shun CT, et al. Colonic leucine-rich repeat kinase 2 expression is increased and associated with disease severity in patients with Parkinson's disease. Front Aging Neurosci. 2021;13:819373.
Lin CH, Lin HY, Ho EP, et al. Mild chronic colitis triggers parkinsonism in LRRK2 mutant mice through activating TNF-alpha pathway. Mov Disord. 2022;37:745-757.
Cabezudo D, Tsafaras G, Van Acker E, Van den Haute C, Baekelandt V. Mutant LRRK2 exacerbates immune response and neurodegeneration in a chronic model of experimental colitis. Acta Neuropathol. 2023;146:245-261.
Sampson TR, Debelius JW, Thron T, et al. Gut Microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016;167:1469-1480.e12.
Erny D, Hrabe de Angelis AL, Jaitin D, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18:965-977.
Manjarres Z, Calvo M, Pacheco R. Regulation of pain perception by microbiota in Parkinson's disease. Pharmacol Rev. 2023;76: 7-36.
Brown GC, Camacho M, Williams-Gray CH. The endotoxin hypothesis of Parkinson's disease. Mov Disord. 2023;38:1143-1155.
Kim TK, Bae EJ, Jung BC, et al. Inflammation promotes synucleinopathy propagation. Exp Mol Med. 2022;54:2148-2161.
Campos-Acuña J, Elgueta D, Pacheco R. T-Cell-Driven inflammation as a mediator of the Gut-brain axis involved in Parkinson's disease. Front Immunol. 2019;10:239.
Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease-From basic research to the clinic. Nat Rev Neurol. 2022;18:476-495.
Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB. Microglial inflammation in the parkinsonian substantia nigra: Relationship to alpha-synuclein deposition. J Neuroinflammation. 2005;2:14.
Doorn KJ, Moors T, Drukarch B, van de Berg W, Lucassen PJ, van Dam AM. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. Acta Neuropathol Commun. 2014;2:90.
McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38:1285-1291.
Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain. 2005;128(Pt 11):2665-2674.
Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol (Berl). 2003;106: 518-526.
Conte C, Ingrassia A, Breve J, et al. Toll-like receptor 4 is upregulated in Parkinson's disease patients and co-localizes with pSer129alphaSyn: A possible link with the pathology. Cells. 2023;12:1368.
Badanjak K, Fixemer S, Smajic S, Skupin A, Grunewald A. The contribution of microglia to neuroinflammation in Parkinson's disease. Int J Mol Sci. 2021;22:4676.
Smajić S, Prada-Medina CA, Landoulsi Z, et al. Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain. 2022;145:964-978.
Kouli A, Camacho M, Allinson K, Williams-Gray CH. Neuroinflammation and protein pathology in Parkinson's disease dementia. Acta Neuropathol Commun. 2020;8:211.
Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis. 2006;21:404-412.
Iannaccone S, Cerami C, Alessio M, et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat Disord. 2013;19: 47-52.
Zhang PF, Gao F. Neuroinflammation in Parkinson's disease: A meta-analysis of PET imaging studies. J Neurol. 2022;269: 2304-2314.
Stokholm MG, Iranzo A, Ostergaard K, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A case-control study. Lancet Neurol. 2017;16:789-796.
Mullin S, Stokholm MG, Hughes D, et al. Brain microglial activation increased in glucocerebrosidase (GBA) mutation carriers without Parkinson's disease. Mov Disord. 2021;36: 774-779.
Terkelsen MH, Klaestrup IH, Hvingelby V, Lauritsen J, Pavese N, Romero-Ramos M. Neuroinflammation and immune changes in prodromal Parkinson's disease and other synucleinopathies. J Parkinsons Dis. 2022;12(s1):S149-S163.
Pillny C, Nitsch L, Proske-Schmitz S, Sharma A, Wüllner U. Abnormal subpopulations of monocytes in the cerebrospinal fluid of patients with Parkinson's disease. Parkinsonism Relat Disord. 2021;84:144-145.
Schröder JB, Pawlowski M, Meyer Zu Hörste G, et al. Immune cell activation in the cerebrospinal fluid of patients with Parkinson's disease. Front Neurol. 2018;9:1081.
Galiano-Landeira J, Torra A, Vila M, Bové J. CD8 t cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease. Brain. 2020;143:3717-3733.
Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119: 182-192.
Pey P, Pearce RK, Kalaitzakis ME, Griffin WS, Gentleman SM. Phenotypic profile of alternative activation marker CD163 is different in Alzheimer's and Parkinson's disease. Acta Neuropathol Commun. 2014;2:21.
Nissen SK, Ferreira SA, Nielsen MC, et al. Soluble CD163 changes indicate monocyte association with cognitive deficits in Parkinson's disease. Mov Disord. 2021;36:963-976.
Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology. 2013;38:938-949.
Yacoubian TA, Fang YD, Gerstenecker A, et al. Brain and systemic inflammation in De Novo Parkinson's disease. Mov Disord. 2023;38:743-754.
Kouli A, Spindler LRB, Fryer TD, et al. Neuroinflammation is linked to dementia risk in Parkinson's disease. Brain. 2024; 147:923-935.
Mogi M, Harada M, Kondo T, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett. 1994;180:147-150.
Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165(1-2):208-210.
Chen X, Hu Y, Cao Z, Liu Q, Cheng Y. Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Front Immunol. 2018;9:2122.
Harms AS, Ferreira SA, Romero-Ramos M. Periphery and brain, innate and adaptive immunity in Parkinson's disease. Acta Neuropathol. 2021;141:527-545.
Gao HM, Hong JS, Zhang W, Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci. 2002;22:782-790.
Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration. 1996;5:137-143.
Campolo M, Paterniti I, Siracusa R, Filippone A, Esposito E, Cuzzocrea S. TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson's diseases in vivo model. Brain Behav Immun. 2019;76:236-247.
Shao QH, Chen Y, Li FF, et al. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease. Acta Pharmacol Sin. 2019;40:1503-1512.
Schintu N, Frau L, Ibba M, Garau A, Carboni E, Carta AR. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox Res. 2009;16:127-139.
Muñoz-Manchado AB, Villadiego J, Romo-Madero S, et al. Chronic and progressive Parkinson's disease MPTP model in adult and aged mice. J Neurochem. 2016;136:373-387.
Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging. 2008;29:1690-1701.
Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009;106:13010-13015.
Lee HJ, Suk JE, Patrick C, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem. 2010;285:9262-9272.
Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: A process leading to disease progression in Parkinson's disease. FASEB J. 2005;19:533-542.
Zhang W, Dallas S, Zhang D, et al. Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia. 2007;55:1178-1188.
Klegeris A, Pelech S, Giasson BI, et al. Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging. 2008;29:739-752.
Hoenen C, Gustin A, Birck C, et al. Alpha-Synuclein proteins promote pro-inflammatory cascades in microglia: Stronger effects of the A53T mutant. PLoS One. 2016;11:e0162717.
Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol. 2008;67:1149-1158.
Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci. 2009;29:3365-3373.
Barkholt P, Sanchez-Guajardo V, Kirik D, Romero-Ramos M. Long-term polarization of microglia upon alpha-synuclein overexpression in nonhuman primates. Neuroscience. 2012; 208:85-96.
Earls RH, Menees KB, Chung J, et al. Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice. J Neuroinflammation. 2019;16:250.
Thomsen MB, Ferreira SA, Schacht AC, et al. PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. Neurobiol Dis. 2021;149:105229.
Boi L, Pisanu A, Palmas MF, et al. Modeling Parkinson's disease neuropathology and symptoms by intranigral inoculation of preformed human alpha-synuclein oligomers. Int J Mol Sci. 2020;21:8535.
Manchinu MF, Pala M, Palmas MF, et al. Region-specific changes in gene expression are associated with cognitive deficits in the alpha-synuclein-induced model of Parkinson's disease: A transcriptomic profiling study. Exp Neurol. 2024;372: 114651.
Park JY, Paik SR, Jou I, Park SM. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: Implications for Parkinson's disease. Glia. 2008;56: 1215-1223.
Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK. Toll-Like receptor 4 promotes alpha-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol. 2011;179:954-963.
Xia Y, Zhang G, Kou L, et al. Reactive microglia enhance the transmission of exosomal alpha-synuclein via toll-like receptor 2. Brain. 2021;144:2024-2037.
Fellner L, Irschick R, Schanda K, et al. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia. 2013;61:349-360.
Venezia S, Refolo V, Polissidis A, Stefanis L, Wenning GK, Stefanova N. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal alpha-synucleinopathy. Mol Neurodegener. 2017;12:52.
Kim C, Ho DH, Suk JE, et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562.
Codolo G, Plotegher N, Pozzobon T, et al. Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS One. 2013;8:e55375.
Choi I, Zhang Y, Seegobin SP, et al. Microglia clear neuron-released alpha-synuclein via selective autophagy and prevent neurodegeneration. Nat Commun. 2020;11:1386.
Roodveldt C, Labrador-Garrido A, Gonzalez-Rey E, et al. Preconditioning of microglia by alpha-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. PLoS One. 2013;8:e79160.
Daniele SG, Béraud D, Davenport C, Cheng K, Yin H, Maguire-Zeiss KA. Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders. Sci Signal. 2015;8:ra45.
Feng Y, Zheng C, Zhang Y, et al. Triptolide inhibits preformed fibril-induced microglial activation by targeting the MicroRNA155-5p/SHIP1 pathway. Oxid Med Cell Longev. 2019; 2019:6527638.
Belitskaia RA, Shumova OV, Oberg OK, Levashova II, Bragin EO. [The sympathetic-adrenal system during reflex analgesia used in the treatment of a pathological preliminary period]. Akush Ginekol (Mosk). 1989;11:27-30.
Gustot A, Gallea JI, Sarroukh R, Celej MS, Ruysschaert JM, Raussens V. Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease. Biochem J. 2015;471:323-333.
Scheiblich H, Bousset L, Schwartz S, et al. Microglial NLRP3 inflammasome activation upon TLR2 and TLR5 ligation by distinct α-synuclein assemblies. J Immunol. 2021;207:2143-2154.
Venezia S, Kaufmann WA, Wenning GK, Stefanova N. Toll-like receptor 4 deficiency facilitates alpha-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease. Parkinsonism Relat Disord. 2021;91:59-65.
Cheng Y, Tong Q, Yuan Y, et al. α-Synuclein induces prodromal symptoms of Parkinson's disease via activating TLR2/MyD88/ NF-κB pathway in Schwann cells of vagus nerve in a rat model. J Neuroinflammation. 2023;20:36.
Dutta D, Jana M, Majumder M, Mondal S, Roy A, Pahan K. Selective targeting of the TLR2/MyD88/NF-kappaB pathway reduces alpha-synuclein spreading in vitro and in vivo. Nat Commun. 2021;12:5382.
Su X, Federoff HJ, Maguire-Zeiss KA. Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res. 2009;16:238-254.
Panicker N, Sarkar S, Harischandra DS, et al. Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia. J Exp Med. 2019;216:1411-1430.
Zhou Y, Lu M, Du RH, et al. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease. Mol Neurodegener. 2016;11:28.
Pike AF, Varanita T, Herrebout MAC, et al. α-Synuclein evokes NLRP3 inflammasome-mediated IL-1β secretion from primary human microglia. Glia. 2021;69:1413-1428.
Trudler D, Nazor KL, Eisele YS, et al. Soluble α-synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia. Proc Natl Acad Sci U S A. 2021;118:e2025847118.
Lee E, Hwang I, Park S, et al. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 2019;26:213-228.
Gordon R, Albornoz EA, Christie DC, et al. Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. 2018;10: eaah4066.
Grotemeyer A, Fischer JF, Koprich JB, et al. Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease. J Neuroinflammation. 2023;20:79.
Mao Z, Liu C, Ji S, et al. The NLRP3 inflammasome is involved in the pathogenesis of Parkinson's disease in rats. Neurochem Res. 2017;42:1104-1115.
Zhang Y, Feng S, Nie K, et al. TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease. Biochem Biophys Res Commun. 2018;499:797-802.
Guo Y, Wei X, Yan H, et al. TREM2 deficiency aggravates α-synuclein-induced neurodegeneration and neuroinflammation in Parkinson's disease models. FASEB J. 2019;33: 12164-12174.
Ren M, Guo Y, Wei X, et al. TREM2 overexpression attenuates neuroinflammation and protects dopaminergic neurons in experimental models of Parkinson's disease. Exp Neurol. 2018; 302:205-213.
Huang W, Lv Q, Xiao Y, et al. Triggering receptor expressed on myeloid cells 2 protects dopaminergic neurons by promoting autophagy in the inflammatory pathogenesis of Parkinson's disease. Front Neurosci. 2021;15:745815.
Filippini A, Gennarelli M, Russo I. Leucine-rich repeat kinase 2-related functions in GLIA: An update of the last years. Biochem Soc Trans. 2021;49:1375-1384.
Gillardon F, Schmid R, Draheim H. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience. 2012;208:41-48.
Kim KS, Marcogliese PC, Yang J, et al. Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease. Proc Natl Acad Sci U S A. 2018;115: E5164-E5173.
Ahmadi Rastegar D, Hughes LP, Perera G, et al. Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. NPJ Parkinsons Dis. 2022; 8:34.
Russo I, Kaganovich A, Ding J, et al. Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory-and oxidative stress-related pathways upon treatment with alpha-synuclein fibrils. Neurobiol Dis. 2019; 129:67-78.
Kim C, Beilina A, Smith N, et al. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Sci Transl Med. 2020;12:eaay0399.
Ho DH, Nam D, Seo M, Park SW, Seol W, Son I. LRRK2 inhibition mitigates the neuroinflammation caused by TLR2-specific alpha-synuclein and alleviates neuroinflammation-derived dopaminergic neuronal loss. Cells. 2022;11:861.
Harms AS, Cao S, Rowse AL, et al. MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci. 2013;33:9592-9600.
Kim S, Pajarillo E, Nyarko-Danquah I, Aschner M, Lee E. Role of astrocytes in Parkinson's disease associated with genetic mutations and neurotoxicants. Cells. 2023;12:622.
Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017; 541:481-487.
Zeljkovic Jovanovic M, Stanojevic J, Stevanovic I, et al. Intermittent theta burst stimulation improves motor and behavioral dysfunction through modulation of NMDA receptor subunit composition in experimental model of Parkinson's disease. Cells. 2023;12:1525.
Chung EK, Chen LW, Chan YS, Yung KK. Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine-lesioned rats. J Comp Neurol. 2008;511:421-437.
Iovino L, Giusti V, Pischedda F, et al. Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease. Acta Neuropathol. 2022;144:81-106.
Morales I, Sanchez A, Rodriguez-Sabate C, Rodriguez M. Striatal astrocytes engulf dopaminergic debris in Parkinson's disease: A study in an animal model. PLoS One. 2017;12: e0185989.
Song YJ, Halliday GM, Holton JL, et al. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol. 2009;68: 1073-1083.
Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol. 2000;99:14-20.
Braidy N, Gai WP, Xu YH, et al. Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts. Transl Neurodegener. 2013;2:20.
Loria F, Vargas JY, Bousset L, et al. α-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading. Acta Neuropathol. 2017;134:789-808.
Rostami J, Mothes T, Kolahdouzan M, et al. Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates. J Neuroinflammation. 2021;18:124.
Rostami J, Holmqvist S, Lindström V, et al. Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes. J Neurosci. 2017;37:11835-11853.
Chou TW, Chang NP, Krishnagiri M, et al. Fibrillar α-synuclein induces neurotoxic astrocyte activation via RIP kinase signaling and NF-κB. Cell Death Dis. 2021;12:756.
Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, McGeer PL. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J. 2006;20:2000-2008.
Erustes AG, Stefani FY, Terashima JY, et al. Overexpression of α-synuclein in an astrocyte cell line promotes autophagy inhibition and apoptosis. J Neurosci Res. 2018;96:160-171.
Gu XL, Long CX, Sun L, Xie C, Lin X, Cai H. Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol Brain. 2010;3:12.
Liu M, Qin L, Wang L, et al. α-synuclein induces apoptosis of astrocytes by causing dysfunction of the endoplasmic reticulum-Golgi compartment. Mol Med Rep. 2018;18:322-332.
Yun SP, Kam TI, Panicker N, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nat Med. 2018;24:931-938.
Gray MT, Woulfe JM. Striatal blood-brain barrier permeability in Parkinson's disease. J Cereb Blood Flow Metab. 2015;35:747-750.
Al-Bachari S, Naish JH, Parker GJM, Emsley HCA, Parkes LM. Blood-Brain barrier leakage is increased in Parkinson's disease. Front Physiol. 2020;11:593026.
Zhao C, Ling Z, Newman MB, Bhatia A, Carvey PM. TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis. 2007;26: 36-46.
Heithoff BP, George KK, Phares AN, Zuidhoek IA, Munoz-Ballester C, Robel S. Astrocytes are necessary for blood-brain barrier maintenance in the adult mouse brain. Glia. 2021;69: 436-472.
de Rus Jacquet A, Alpaugh M, Denis HL, et al. The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson's disease. Nat Commun. 2023;14:3651.
Liu Z, Qiu AW, Huang Y, et al. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease. Brain Behav Immun. 2019; 81:630-645.
Sommer A, Fadler T, Dorfmeister E, et al. Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model. J Neuroinflammation. 2016;13:174.
Tentillier N, Etzerodt A, Olesen MN, et al. Anti-Inflammatory modulation of microglia via CD163-targeted glucocorticoids protects dopaminergic neurons in the 6-OHDA Parkinson's disease model. J Neurosci. 2016;36:9375-9390.
Rostami J, Fotaki G, Sirois J, et al. Astrocytes have the capacity to act as antigen-presenting cells in the Parkinson's disease brain. J Neuroinflammation. 2020;17:119.
Martin HL, Santoro M, Mustafa S, Riedel G, Forrester JV, Teismann P. Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease. Glia. 2016;64:386-395.
Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol. 2006;197:275-283.
Lind-Holm Mogensen F, Scafidi A, Poli A, Michelucci A. PARK7/ DJ-1 in microglia: Implications in Parkinson's disease and relevance as a therapeutic target. J Neuroinflammation. 2023;20:95.
Adebonojo SA, Jaiyesimi F. Pericardioperitoneal shunt for massive recurrent pericardial effusion in patients with endomyocardial fibrosis. Int Surg. 1977;62(6-7):349-350.
Meiser J, Delcambre S, Wegner A, et al. Loss of DJ-1 impairs antioxidant response by altered glutamine and serine metabolism. Neurobiol Dis. 2016;89:112-125.
Ji YJ, Wang HL, Yin BL, Ren XY. Down-regulation of DJ-1 augments neuroinflammation via Nrf2/Trx1/NLRP3 axis in MPTP-induced Parkinson's disease mouse model. Neuroscience. 2020;442:253-263.
Kim RH, Smith PD, Aleyasin H, et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A. 2005;102:5215-5220.
Chien CH, Lee MJ, Liou HC, Liou HH, Fu WM. Microglia-Derived cytokines/chemokines are involved in the enhancement of LPS-induced loss of nigrostriatal dopaminergic neurons in DJ-1 knockout mice. PLoS One. 2016;11:e0151569.
Bandopadhyay R, Kingsbury AE, Cookson MR, et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain. 2004;127(Pt 2): 420-430.
Frøyset AK, Edson AJ, Gharbi N, et al. Astroglial DJ-1 over-expression up-regulates proteins involved in redox regulation and is neuroprotective in vivo. Redox Biol. 2018;16:237-247.
De Miranda BR, Rocha EM, Bai Q, et al. Astrocyte-specific DJ-1 overexpression protects against rotenone-induced neurotoxicity in a rat model of Parkinson's disease. Neurobiol Dis. 2018; 115:101-114.
Lindström V, Gustafsson G, Sanders LH, et al. Extensive uptake of alpha-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage. Mol Cell Neurosci. 2017;82:143-156.
Sarkar S, Malovic E, Harishchandra DS, et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson's disease. NPJ Parkinsons Dis. 2017;3:30.
Ahmed S, Panda SR, Kwatra M, Sahu BD, Naidu V. Perillyl alcohol attenuates NLRP3 inflammasome activation and rescues dopaminergic neurons in experimental in vitro and in vivo models of Parkinson's disease. ACS Chem Neurosci. 2022;13: 53-68.
Yan Y, Jiang W, Liu L, et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell. 2015;160(1-2):62-73.
Shao W, Zhang SZ, Tang M, et al. Suppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallin. Nature. 2013;494:90-94.
Montoya A, Elgueta D, Campos J, et al. Dopamine receptor D3 signalling in astrocytes promotes neuroinflammation. J Neuroinflammation. 2019;16:258.
Sliter DA, Martinez J, Hao L, et al. Parkin and PINK1 mitigate STING-induced inflammation. Nature. 2018;561:258-262.
Hinkle JT, Patel J, Panicker N, et al. STING mediates neurodegeneration and neuroinflammation in nigrostriatal alpha-synucleinopathy. Proc Natl Acad Sci U S A. 2022;119: e2118819119.
Szego EM, Malz L, Bernhardt N, Rösen-Wolff A, Falkenburger BH, Luksch H. Constitutively active STING causes neuroinflammation and degeneration of dopaminergic neurons in mice. Elife. 2022;11:e81943.
Ma C, Liu Y, Li S, et al. Microglial cGAS drives neuroinflammation in the MPTP mouse models of Parkinson's disease. CNS Neurosci Ther. 2023;29:2018-2035.
Scheiblich H, Dansokho C, Mercan D, et al. Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell. 2021;184:5089-5106.e21.
Choi I, Heaton GR, Lee YK, Yue Z. Regulation of alpha-synuclein homeostasis and inflammasome activation by microglial autophagy. Sci Adv. 2022;8:eabn1298.
Tu HY, Yuan BS, Hou XO, et al. alpha-synuclein suppresses microglial autophagy and promotes neurodegeneration in a mouse model of Parkinson's disease. Aging Cell. 2021;20: e13522.
Bido S, Muggeo S, Massimino L, et al. Microglia-specific overexpression of alpha-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity. Nat Commun. 2021;12:6237.
Qin Y, Qiu J, Wang P, et al. Impaired autophagy in microglia aggravates dopaminergic neurodegeneration by regulating NLRP3 inflammasome activation in experimental models of Parkinson's disease. Brain Behav Immun. 2021;91: 324-338.
Cheng J, Liao Y, Dong Y, et al. Microglial autophagy defect causes Parkinson disease-like symptoms by accelerating inflammasome activation in mice. Autophagy. 2020;16:2193-2205.
Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ. Non-classical exocytosis of α-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem. 2010;113: 1263-1274.
Alvarez-Erviti L, Seow Y, Schapira AH, et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 2011;42:360-367.
Hansen C, Angot E, Bergström AL, et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest. 2011;121: 715-725.
Lee HJ, Suk JE, Bae EJ, Lee SJ. Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun. 2008;372:423-428.
Xia Y, Zhang G, Han C, et al. Microglia as modulators of exosomal alpha-synuclein transmission. Cell Death Dis. 2019;10:174.
Guo M, Wang J, Zhao Y, et al. Microglial exosomes facilitate α-synuclein transmission in Parkinson's disease. Brain. 2020; 143:1476-1497.
Chakraborty R, Nonaka T, Hasegawa M, Zurzolo C. Tunnelling nanotubes between neuronal and microglial cells allow bi-directional transfer of α-synuclein and mitochondria. Cell Death Dis. 2023;14:329.
Morganti JM, Nash KR, Grimmig BA, et al. The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease. J Neurosci. 2012;32:14592-14601.
Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinflammation. 2011;8:9.
Nash KR, Moran P, Finneran DJ, et al. Fractalkine over expression suppresses α-synuclein-mediated neurodegeneration. Mol Ther. 2015;23:17-23.
Gupta M, Paliwal VK, Babu GN. Serum fractalkine and 3-nitrotyrosine levels correlate with disease severity in Parkinson's disease: A pilot study. Metab Brain Dis. 2022;37:209-217.
Castro-Sánchez S, García-Yagüe AJ, López-Royo T, Casarejos M, Lanciego JL, Lastres-Becker I. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease. Glia. 2018;66:1752-1762.
Thome AD, Standaert DG, Harms AS. Fractalkine signaling regulates the inflammatory response in an α-synuclein model of Parkinson disease. PLoS One. 2015;10:e0140566.
Wang XJ, Zhang S, Yan ZQ, et al. Impaired CD200-CD200R-mediated microglia silencing enhances midbrain dopaminergic neurodegeneration: Roles of aging, superoxide, NADPH oxidase, and p38 MAPK. Free Radic Biol Med. 2011;50:1094-1106.
Zhang S, Wang XJ, Tian LP, et al. CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. J Neuroinflammation. 2011;8:154.
Rabaneda-Lombarte N, Serratosa J, Bové J, Vila M, Saura J, Solà C. The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson's disease. J Neuroinflammation. 2021;18:88.
Wang L, Liu Y, Yan S, et al. Disease progression-dependent expression of CD200R1 and CX3CR1 in mouse models of Parkinson's disease. Aging Dis. 2020;11:254-268.
Leggio L, L'Episcopo F, Magrì A, et al. Small extracellular vesicles secreted by nigrostriatal astrocytes rescue cell death and preserve mitochondrial function in Parkinson's disease. Adv Healthc Mater. 2022;11:e2201203.
de Rus Jacquet A, Tancredi JL, Lemire AL, DeSantis MC, Li WP, O'Shea EK. The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson's disease. Elife. 2021;10:e73062.
Cavaliere F, Cerf L, Dehay B, et al. In vitro alpha-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains. Neurobiol Dis. 2017;103:101-112.
Pantazopoulou M, Lamprokostopoulou A, Karampela DS, et al. Differential intracellular trafficking of extracellular vesicles in microglia and astrocytes. Cell Mol Life Sci. 2023;80:193.
di Domenico A, Carola G, Calatayud C, et al. Patient-Specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson's disease. Stem Cell Reports. 2019;12:213-229.
Craig DW, Hutchins E, Violich I, et al. RNA sequencing of whole blood reveals early alterations in immune cells and gene expression in Parkinson's disease. Nature Aging. 2021;1:734-747.
Jensen MP, Jacobs BM, Dobson R, et al. Lower lymphocyte count is associated with increased risk of Parkinson's disease. Ann Neurol. 2021;89:803-812.
Sun C, Zhao Z, Yu W, et al. Abnormal subpopulations of peripheral blood lymphocytes are involved in Parkinson's disease. Ann Transl Med. 2019;7:637.
Grillo P, Sancesario GM, Bovenzi R, et al. Neutrophil-to-lymphocyte ratio and lymphocyte count reflect alterations in central neurodegeneration-associated proteins and clinical severity in Parkinson disease patients. Parkinsonism Relat Disord. 2023;112:105480.
Sanjari Moghaddam H, Ghazi Sherbaf F, Mojtahed Zadeh M, Ashraf-Ganjouei A, Aarabi MH. Association between peripheral inflammation and DATSCAN data of the striatal nuclei in different motor subtypes of Parkinson disease. Front Neurol. 2018;9:234.
Umehara T, Oka H, Nakahara A, Matsuno H, Murakami H. Differential leukocyte count is associated with clinical phenotype in Parkinson's disease. J Neurol Sci. 2020; 409:116638.
Contaldi E, Magistrelli L, Cosentino M, Marino F, Comi C. Lymphocyte count and neutrophil-to-lymphocyte ratio are associated with mild cognitive impairment in Parkinson's disease: A single-center longitudinal study. J Clin Med. 2022;11: 5543.
Magistrelli L, Storelli E, Rasini E, et al. Relationship between circulating CD4+ T lymphocytes and cognitive impairment in patients with Parkinson's disease. Brain Behav Immun. 2020; 89:668-674.
Patel AA, Zhang Y, Fullerton JN, et al. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. J Exp Med. 2017;214:1913-1923.
Álvarez-Luquín DD, Arce-Sillas A, Leyva-Hernández J, et al. Regulatory impairment in untreated Parkinson's disease is not restricted to Tregs: Other regulatory populations are also involved. J Neuroinflammation. 2019;16:212.
da Silva DJ, Borges AF, Souza PO, et al. Decreased toll-like receptor 2 and toll-like receptor 7/8-induced cytokines in Parkinson's disease patients. Neuroimmunomodulation. 2016; 23:58-66.
Drouin-Ouellet J, St-Amour I, Saint-Pierre M, et al. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease. Int J Neuropsychopharmacol. 2014; 18:pyu103.
Schlachetzki JCM, Prots I, Tao J, et al. A monocyte gene expression signature in the early clinical course of Parkinson's disease. Sci Rep. 2018;8:10757.
Green H, Zhang X, Tiklova K, et al. Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinson's disease. Proc Natl Acad Sci U S A. 2017;114:2735-2740.
Grozdanov V, Bliederhaeuser C, Ruf WP, et al. Inflammatory dysregulation of blood monocytes in Parkinson's disease patients. Acta Neuropathol. 2014;128:651-663.
Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, et al. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease. Brain Behav Immun. 2020;87:473-488.
Su Y, Shi C, Wang T, et al. Dysregulation of peripheral monocytes and pro-inflammation of alpha-synuclein in Parkinson's disease. J Neurol. 2022;269:6386-6394.
Farmen K, Nissen SK, Stokholm MG, et al. Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. Proc Natl Acad Sci U S A. 2021;118: e2020858118.
Konstantin Nissen S, Farmen K, Carstensen M, et al. Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinson's disease and cognition. Brain Behav Immun. 2022;101:182-193.
Thome AD, Atassi F, Wang J, et al. Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson's disease. NPJ Parkinsons Dis. 2021; 7:41.
Tian J, Dai SB, Jiang SS, et al. Specific immune status in Parkinson's disease at different ages of onset. NPJ Parkinsons Dis. 2022;8:5.
Navarro E, Udine E, de Paiva Lopes K, et al. Dysregulation of mitochondrial and proteolysosomal genes in Parkinson's disease myeloid cells. Nat Aging. 2021;1:850-863.
Carlisle SM, Qin H, Hendrickson RC, et al. Sex-based differences in the activation of peripheral blood monocytes in early Parkinson disease. NPJ Parkinsons Dis. 2021;7:36.
Funk N, Wieghofer P, Grimm S, et al. Characterization of peripheral hematopoietic stem cells and monocytes in Parkinson's disease. Mov Disord. 2013;28:392-395.
Nissen SK, Shrivastava K, Schulte C, et al. Alterations in blood monocyte functions in Parkinson's disease. Mov Disord. 2019; 34:1711-1721.
Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, et al. Monocyte function in Parkinson's disease and the impact of autologous serum on phagocytosis. Front Neurol. 2018;9:870.
Bhatia D, Grozdanov V, Ruf WP, et al. T-cell dysregulation is associated with disease severity in Parkinson's disease. J Neuroinflammation. 2021;18:250.
Jiang S, Gao H, Luo Q, Wang P, Yang X. The correlation of lymphocyte subsets, natural killer cell, and Parkinson's disease: A meta-analysis. Neurol Sci. 2017;38:1373-1380.
Karaaslan Z, Kahraman OT, Şanli E, et al. Inflammation and regulatory T cell genes are differentially expressed in peripheral blood mononuclear cells of Parkinson's disease patients. Sci Rep. 2021;11:2316.
Sommer A, Marxreiter F, Krach F, et al. Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson's disease. Cell Stem Cell. 2018;23:123-131.e6.
Kustrimovic N, Comi C, Magistrelli L, et al. Parkinson's disease patients have a complex phenotypic and functional Th1 bias: Cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naive and drug-treated patients. J Neuroinflammation. 2018;15:205.
Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord. 2005;11:493-498.
Chen Y, Qi B, Xu W, et al. Clinical correlation of peripheral CD4+-cell sub-sets, their imbalance and Parkinson's disease. Mol Med Rep. 2015;12:6105-6111.
Yan Z, Yang W, Wei H, et al. Dysregulation of the adaptive immune system in patients with early-stage Parkinson disease. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1036.
He Y, Peng K, Li R, et al. Changes of T lymphocyte subpopulations and their roles in predicting the risk of Parkinson's disease. J Neurol. 2022;269:5368-5381.
Stevens CH, Rowe D, Morel-Kopp MC, et al. Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol. 2012;252(1-2):95-99.
Saunders JA, Estes KA, Kosloski LM, et al. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol. 2012;7:927-938.
Wang P, Yao L, Luo M, et al. Single-cell transcriptome and TCR profiling reveal activated and expanded T cell populations in Parkinson's disease. Cell Discov. 2021;7:52.
Williams-Gray CH, Wijeyekoon RS, Scott KM, Hayat S, Barker RA, Jones JL. Abnormalities of age-related T cell senescence in Parkinson's disease. J Neuroinflammation. 2018;15:166.
Kouli A, Jensen M, Papastavrou V, et al. T lymphocyte senescence is attenuated in Parkinson's disease. J Neuroinflammation. 2021;18:228.
Vavilova JD, Boyko AA, Ponomareva NV, et al. Reduced immunosenescence of peripheral blood T cells in Parkinson's disease with CMV infection background. Int J Mol Sci. 2021;22: 13119.
Sulzer D, Alcalay RN, Garretti F, et al. T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature. 2017;546:656-661.
Lindestam Arlehamn CS, Dhanwani R, Pham J, et al. α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. Nat Commun. 2020; 11:1875.
Dhanwani R, Lima-Junior JR, Sethi A, et al. Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures. NPJ Parkinsons Dis. 2022;8:30.
Horvath S, Ritz BR. Increased epigenetic age and granulocyte counts in the blood of Parkinson's disease patients. Aging (Albany NY). 2015;7:1130-1142.
Zhao X, Jin T, Zheng C, Ma D, Zhang Y. Imbalance of circulating Tfh/Tfr cells in patients with Parkinson's disease. Front Neurol. 2020;11:572205.
Bas J, Calopa M, Mestre M, et al. Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol. 2001;113:146-152.
Wang P, Luo M, Zhou W, et al. Global characterization of peripheral B cells in Parkinson's disease by single-cell RNA and BCR sequencing. Front Immunol. 2022;13:814239.
Li R, Tropea TF, Baratta LR, et al. Abnormal B-cell and Tfh-cell profiles in patients with Parkinson disease: A cross-sectional study. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1125.
Scott KM. B lymphocytes in Parkinson's disease. J Parkinsons Dis. 2022;12(s1):S75-S81.
Scott KM, Chong YT, Park S, et al. B lymphocyte responses in Parkinson's disease and their possible significance in disease progression. Brain Commun. 2023;5:fcad060.
Scott KM, Kouli A, Yeoh SL, Clatworthy MR, Williams-Gray CH. A systematic review and meta-analysis of alpha synuclein auto-antibodies in Parkinson's disease. Front Neurol. 2018;9: 815.
Double KL, Rowe DB, Carew-Jones FM, et al. Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol. 2009;217:297-301.
Benkler M, Agmon-Levin N, Hassin-Baer S, et al. Immunology, autoimmunity, and autoantibodies in Parkinson's disease. Clin Rev Allergy Immunol. 2012;42:164-171.
Folke J, Bergholt E, Pakkenberg B, Aznar S, Brudek T. Alpha-Synuclein autoimmune decline in prodromal multiple system atrophy and Parkinson's disease. Int J Mol Sci. 2022;23: 6554.
Folke J, Rydbirk R, Løkkegaard A, et al. Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease. Parkinsonism Relat Disord. 2021;87:98-104.
Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y. Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: A systematic review and meta-analysis. JAMA Neurol. 2016;73: 1316-1324.
Rathnayake D, Chang T, Udagama P. Selected serum cytokines and nitric oxide as potential multi-marker biosignature panels for Parkinson disease of varying durations: A case-control study. BMC Neurol. 2019;19:56.
Williams-Gray CH, Wijeyekoon R, Yarnall AJ, et al. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). Mov Disord. 2016;31: 995-1003.
Mollenhauer B, Zimmermann J, Sixel-Döring F, et al. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson cohort (DeNoPa). Mov Disord. 2019;34:67-77.
Ahmadi Rastegar D, Ho N, Halliday GM, Dzamko N. Parkinson's progression prediction using machine learning and serum cytokines. NPJ Parkinsons Dis. 2019;5:14.
Grozdanov V, Bousset L, Hoffmeister M, et al. Increased immune activation by pathologic alpha-synuclein in Parkinson's disease. Ann Neurol. 2019;86:593-606.
Piancone F, Saresella M, La Rosa F, et al. Inflammatory responses to monomeric and aggregated α-synuclein in peripheral blood of Parkinson disease patients. Front Neurosci. 2021; 15:639646.
White AJ, Wijeyekoon RS, Scott KM, et al. The peripheral inflammatory response to alpha-synuclein and endotoxin in Parkinson's disease. Front Neurol. 2018;9:946.
Dantzer R. Neuroimmune interactions: From the brain to the immune system and vice versa. Physiol Rev. 2018;98:477-504.
Wijeyekoon RS, Moore SF, Farrell K, Breen DP, Barker RA, Williams-Gray CH. Cerebrospinal fluid cytokines and neurodegeneration-associated proteins in Parkinson's disease. Mov Disord. 2020;35:1062-1066.
Albayram MS, Smith G, Tufan F, et al. Non-invasive MR imaging of human brain lymphatic networks with connections to cervical lymph nodes. Nat Commun. 2022;13:203.
Castellani G, Croese T, Peralta Ramos JM, Schwartz M. Transforming the understanding of brain immunity. Science. 2023;380:eabo7649.
Muñoz-Delgado L, Labrador-Espinosa MA, Macías-García D, et al. Peripheral inflammation is associated with dopaminergic degeneration in Parkinson's disease. Mov Disord. 2023;38: 755-763.
Contaldi E, Magistrelli L, Furgiuele A, Gallo S, Comi C. Relationship between [(123)I]FP-CIT SPECT data and peripheral CD4 + T cell profile in newly-diagnosed drug-naive Parkinson's disease patients. J Neurol. 2023;270:2776-2783.
Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One. 2010;5:e8784.
Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS. CD4 t cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson disease. Brain. 2021;144:2047-2059.
Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the alpha-synuclein rAAV Parkinson's model. Exp Neurol. 2013;247:45-58.
Li W, Chen S, Luo Y, et al. Interaction between ICAM1 in endothelial cells and LFA1 in T cells during the pathogenesis of experimental Parkinson's disease. Exp Ther Med. 2020;20: 1021-1029.
Karikari AA, McFleder RL, Ribechini E, et al. Neurodegeneration by alpha-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson's disease mice. Brain Behav Immun. 2022;101: 194-210.
González H, Contreras F, Pacheco R. Regulation of the neurodegenerative process associated to Parkinson's disease by CD4+ T-cells. J Neuroimmune Pharmacol. 2015;10:561-575.
González H, Pacheco R. T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. J Neuroinflammation. 2014;11:201.
Cebrián C, Zucca FA, Mauri P, et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun. 2014;5:3633.
Wang BY, Ye YY, Qian C, et al. Stress increases MHC-I expression in dopaminergic neurons and induces autoimmune activation in Parkinson's disease. Neural Regen Res. 2021;16: 2521-2527.
Matheoud D, Cannon T, Voisin A, et al. Intestinal infection triggers Parkinson's disease-like symptoms in pink1(-/-) mice. Nature. 2019;571:565-569.
Chu WT, Hall J, Gurrala A, et al. Evaluation of an adoptive cellular therapy-based vaccine in a transgenic mouse model of α-synucleinopathy. ACS Chem Neurosci. 2023;14:235-245.
George S, Tyson T, Rey NL, et al. T cells limit accumulation of aggregate pathology following intrastriatal injection of α-synuclein fibrils. J Parkinsons Dis. 2021;11:585-603.
Ip CW, Beck SK, Volkmann J. Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease. J Neural Transm (Vienna). 2015;122:1633-1643.
Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M. α-Synuclein vaccination prevents the accumulation of Parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J Neuropathol Exp Neurol. 2013;72:624-645.
Villadiego J, Labrador-Garrido A, Franco JM, et al. Immunization with α-synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model. Glia. 2018;66:191-205.
Rockenstein E, Ostroff G, Dikengil F, et al. Combined active humoral and cellular immunization approaches for the treatment of synucleinopathies. J Neurosci. 2018;38:1000-1014.
Volc D, Poewe W, Kutzelnigg A, et al. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: A randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020;19:591-600.
Lemos M, Venezia S, Refolo V, et al. Targeting α-synuclein by PD03 AFFITOPE(R) and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: Clinical relevance. Transl Neurodegener. 2020;9:38.
Kim C, Hovakimyan A, Zagorski K, et al. Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human alpha-synuclein: Prelude for IND enabling studies. NPJ Vaccines. 2022;7:1.
Liu Z, Zhai XR, Du ZS, et al. Dopamine receptor D2 on CD4(+) T cells is protective against neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease. Brain Behav Immun. 2021;98:110-121.
Li J, Zhao J, Chen L, et al. α-Synuclein induces Th17 differentiation and impairs the function and stability of Tregs by promoting RORC transcription in Parkinson's disease. Brain Behav Immun. 2023;108:32-44.
Liu Z, Huang Y, Cao BB, Qiu YH, Peng YP. Th17 cells induce dopaminergic neuronal death via LFA-1/ICAM-1 interaction in a mouse model of Parkinson's disease. Mol Neurobiol. 2017; 54:7762-7776.
Li W, Luo Y, Xu H, Ma Q, Yao Q. Imbalance between T helper 1 and regulatory T cells plays a detrimental role in experimental Parkinson's disease in mice. J Int Med Res. 2021;49: 300060521998471.
Machhi J, Kevadiya BD, Muhammad IK, et al. Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Mol Neurodegener. 2020; 15:32.
Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol. 2010;184: 2261-2271.
Rothhammer V, Heink S, Petermann F, et al. Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med. 2011;208:2465-2476.
Abeliovich A, Gitler AD. Defects in trafficking bridge Parkinson's disease pathology and genetics. Nature. 2016;539: 207-216.
Gonzalez H, Contreras F, Prado C, et al. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease. J Immunol. 2013;190:5048-5056.
Elgueta D, Aymerich MS, Contreras F, et al. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease. Neuropharmacology. 2017;113(Pt A):110-123.
Rauschenberger L, Behnke J, Grotemeyer A, Knorr S, Volkmann J, Ip CW. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease. Neurobiol Dis. 2022;171: 105798.
Iba M, Kim C, Sallin M, et al. Neuroinflammation is associated with infiltration of T cells in Lewy body disease and α-synuclein transgenic models. J Neuroinflammation. 2020;17:214.
Theodore S, Maragos W. 6-Hydroxydopamine as a tool to understand adaptive immune system-induced dopamine neurodegeneration in Parkinson's disease. Immunopharmacol Immunotoxicol. 2015;37:393-399.
Harms AS, Delic V, Thome AD, et al. α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. Acta Neuropathol Commun. 2017;5:85.
Kalkonde YV, Morgan WW, Sigala J, et al. Chemokines in the MPTP model of Parkinson's disease: Absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration. Brain Res. 2007;1128:1-11.
Harms AS, Thome AD, Yan Z, et al. Peripheral monocyte entry is required for alpha-synuclein induced inflammation and neurodegeneration in a model of Parkinson disease. Exp Neurol. 2018;300:179-187.
Parillaud VR, Lornet G, Monnet Y, et al. Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes. J Neuroinflammation. 2017;14:60.
Schonhoff AM, Figge DA, Williams GP, et al. Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease. Nat Commun. 2023;14:3754.
Oliynyk Z, Rudyk M, Dovbynchuk T, Dzubenko N, Tolstanova G, Skivka L. Inflammatory hallmarks in 6-OHDA-and LPS-induced Parkinson's disease in rats. Brain Behav Immun Health. 2023;30:100616.
Menees KB, Lee JK. New insights and implications of natural killer cells in Parkinson's disease. J Parkinsons Dis. 2022;12(s1): S83-S92.
Earls RH, Menees KB, Chung J, et al. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy. Proc Natl Acad Sci U S A. 2020;117:1762-1771.
Greenland JC, Cutting E, Kadyan S, Bond S, Chhabra A, Williams-Gray CH. Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): A randomised double-blind placebo-controlled phase II trial protocol. BMJ Open. 2020;10:e040527.
